Key baseline clinical characteristics (CNS-IPI risk factors, CNS-IPI score) of patients who developed CNS relapse compared with patients with no CNS relapse and the overall GOYA study population
| Characteristic . | CNS relapse (n = 38) . | No CNS relapse (n = 1380) . | All patients (N = 1418) . |
|---|---|---|---|
| Age, median (range), y | 66.5 (21-81) | 61.0 (18-86) | 62.0 (18-86) |
| <60 | 13 (34.2) | 591 (42.8) | 604 (42.6) |
| ≥60 | 25 (65.8) | 789 (57.2) | 814 (57.4) |
| ECOG PS | |||
| 0-1 | 31 (81.6) | 1200 (87.0) | 1231 (86.9) |
| 2-3 | 7 (18.4) | 179 (13.0) | 186 (13.1) |
| Ann Arbor stage | |||
| I or II | 4 (10.5) | 337 (24.4) | 341 (24.1) |
| III or IV | 34 (89.5) | 1042 (75.6) | 1076 (75.9) |
| Elevated LDH | 26 (68.4) | 790 (57.5) | 816 (57.7) |
| Extranodal sites, n | |||
| 0-1 | 15 (39.5) | 900 (65.2) | 915 (64.5) |
| >1 | 23 (60.5) | 480 (34.8) | 503 (35.5) |
| Involvement of kidneys and/or adrenal glands | 11 (28.9) | 80 (5.8) | 91 (6.4) |
| CNS-IPI | |||
| Low (0-1) | 4 (10.5) | 275 (20.0) | 279 (19.7) |
| Intermediate (2-3) | 16 (42.1) | 878 (63.6) | 894 (63.0) |
| High (4-6) | 18 (47.4) | 227 (16.5) | 245 (17.3) |
| Characteristic . | CNS relapse (n = 38) . | No CNS relapse (n = 1380) . | All patients (N = 1418) . |
|---|---|---|---|
| Age, median (range), y | 66.5 (21-81) | 61.0 (18-86) | 62.0 (18-86) |
| <60 | 13 (34.2) | 591 (42.8) | 604 (42.6) |
| ≥60 | 25 (65.8) | 789 (57.2) | 814 (57.4) |
| ECOG PS | |||
| 0-1 | 31 (81.6) | 1200 (87.0) | 1231 (86.9) |
| 2-3 | 7 (18.4) | 179 (13.0) | 186 (13.1) |
| Ann Arbor stage | |||
| I or II | 4 (10.5) | 337 (24.4) | 341 (24.1) |
| III or IV | 34 (89.5) | 1042 (75.6) | 1076 (75.9) |
| Elevated LDH | 26 (68.4) | 790 (57.5) | 816 (57.7) |
| Extranodal sites, n | |||
| 0-1 | 15 (39.5) | 900 (65.2) | 915 (64.5) |
| >1 | 23 (60.5) | 480 (34.8) | 503 (35.5) |
| Involvement of kidneys and/or adrenal glands | 11 (28.9) | 80 (5.8) | 91 (6.4) |
| CNS-IPI | |||
| Low (0-1) | 4 (10.5) | 275 (20.0) | 279 (19.7) |
| Intermediate (2-3) | 16 (42.1) | 878 (63.6) | 894 (63.0) |
| High (4-6) | 18 (47.4) | 227 (16.5) | 245 (17.3) |
Data are presented as n (%), unless otherwise noted. Data for Eastern Cooperative Oncology Group performance status (ECOG PS) and Ann Arbor Stage were not available in 1 case, and data on lactate dehydrogenase (LDH) were not available in 5 cases. Differences ≥ 10% between CNS relapse/no relapse groups are highlighted in bold type.